je.st
news
Tag: acute
New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes
2015-03-16 20:30:00| Merck.com - Product News
Dateline City: SAN DIEGO SAN DIEGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a pre-specified exploratory analysis of the investigational IMPROVE-IT study of more than 18,000 patients presenting with acute coronary syndromes. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease
2015-03-05 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. These and other post-hoc subgroup analyses from TRA-2°P are being presented at the 2015 American College of Cardiology Scientific Sessions KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of ZONTIVITY (vorapaxar), one of the largest secondary prevention studies of an antiplatelet medicine. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
added
study
reduced
VYTORIN (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
2014-11-17 17:45:00| Merck.com - Product News
Dateline City: CHICAGO CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. Language: English Contact: MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
events
study
reduced
U.S. FDA approves Durata's acute bacterial skin infection drug
2014-05-24 01:29:08| Biotech - Topix.net
The U.S. Food and Drug Administration said on Friday it has approved a new drug to treat acute bacterial skin infections made by Durata Therapeutics Inc. Approval of the drug, Dalvance, follows a positive recommendation by the FDA's advisory committee, which also gave a favorable review to a rival product from Cubist Pharmaceuticals Inc. The FDA is ... (more)
Tags: skin
drug
acute
infection
Chinese Face Acute Worker Shortage on $2B Uganda Dam Project
2014-05-12 15:06:54| ENR.com: Headline News
Chinas Sinohydro Corp. had pledged to create at least 10,000 jobs for Ugandans and Chinese, but has filled only 168 slots.
Tags: project
face
chinese
worker